https://www.selleckchem.com/pr....oducts/solutol-hs-15
Hospital mortality occurred in 27 (13%) non-CGS AHF patients and in 15 (22%) CGS patients (P=0.079). Overall survival at 1 and 5 years in CGS patients was 76% and 69%, respectively, and there were no significant differences in overall survival compared with non-CGS AHF patients (P=1.00. CONCLUSIONS Clinical results after valve surgery in CGS patients remain challenging; however, mid-term results were equivalent to those of non-CGS AHF patients.Vancomycin (VAN) is an anti-microbial agent used to treat a number of bacterial infect
Like
Comment
Share
